New study sheds light on COVID-19 outcomes in patients with rare inborn immune disorders

An international consortium led by Isabelle Meyts (KU Leuven) and Stuart Tangye (Garvan Institute) has published its findings on COVID-19 outcomes in individuals with rare inherited immune disorders known as PIDs. Compared to the general population, these patients had similar disease outcomes, but they were more likely to need intensive care and their average age was lower.
account creation

TO READ THIS ARTICLE, CREATE YOUR ACCOUNT

And extend your reading, free of charge and with no commitment.